All Stories

  1. GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naïve chronic hepatitis C subjects

    Article • Journal of Viral Hepatitis, August 2017, Wiley

    Dr Robert K Hamatake

  2. Pharmacokinetic Characteristics, Pharmacodynamic Effect and In Vivo Antiviral Efficacy of Liver-Targeted Interferon Alpha

    Article • PLoS ONE, February 2015, PLOS

    Dr Robert K Hamatake

  3. Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C

    Article • Liver International, October 2014, Wiley

    Dr Robert K Hamatake, Professor Ben Vainer

  4. P1224 GSK2878175, A POTENT NON-NUCLEOSIDE INHIBITOR OF HCV NS5B WITH PAN-GENOTYPIC ACTIVITY

    Article • Journal of Hepatology, April 2014, Elsevier

    Dr Robert K Hamatake

  5. O119 IN VIVO INHIBITION OF HBV ANTIGENEMIA AND VIREMIA BY ANTISENSE OLIGONUCLEOTIDES

    Article • Journal of Hepatology, April 2014, Elsevier

    Dr Robert K Hamatake

  6. Novel Spiroketal Pyrrolidine GSK2336805 Potently Inhibits Key Hepatitis C Virus Genotype 1b Mutants: From Lead to Clinical Compound

    Article • Journal of Medicinal Chemistry, March 2014, American Chemical Society (ACS)

    Dr Robert K Hamatake

  7. Hepatitis C Replication Inhibitors That Target the Viral NS4B Protein

    Article • Journal of Medicinal Chemistry, March 2014, American Chemical Society (ACS)

    Dr Robert K Hamatake

  8. Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase

    Article • Journal of Medicinal Chemistry, March 2014, American Chemical Society (ACS)

    Dr Robert K Hamatake

  9. A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected

    Article • Liver International, October 2013, Wiley

    Dr Robert K Hamatake

  10. Preclinical Characterization of GSK2336805, a Novel Inhibitor of Hepatitis C Virus Replication That Selects for Resistance in NS5A

    Article • Antimicrobial Agents and Chemotherapy, October 2013, ASM Journals

    Dr Robert K Hamatake

  11. Pharmacological disruption of hepatitis C NS5A protein intra- and intermolecular conformations

    Article • Journal of General Virology, August 2013, Society for General Microbiology

    Dr Robert K Hamatake

  12. In VitroCharacterization of GSK2485852, a Novel Hepatitis C Virus Polymerase Inhibitor

    Article • Antimicrobial Agents and Chemotherapy, August 2013, ASM Journals

    Dr Robert K Hamatake

  13. Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups

    Article • Bioorganic & Medicinal Chemistry Letters, December 2012, Elsevier

    Dr Robert K Hamatake

  14. Discovery of Novel Urea-Based Hepatitis C Protease Inhibitors with High Potency against Protease-Inhibitor-Resistant Mutants

    Article • Journal of Medicinal Chemistry, April 2012, American Chemical Society (ACS)

    Dr Robert K Hamatake

  15. Hepatitis C genotype 1a replicon improved through introduction of fitness mutations

    Article • BioTechniques, April 2012, Informa UK (Informa Life Sciences)

    Dr Robert K Hamatake

  16. Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease

    Article • Bioorganic & Medicinal Chemistry Letters, April 2012, Elsevier

    Dr Robert K Hamatake

  17. HCV Inhibition Mediated Through the Nonstructural Protein 5A (NS5A) Replication Complex

    Article • January 2012, Elsevier

    Dr Robert K Hamatake

  18. 764 IN VITRO PROFILING OF GSK2336805, A POTENT AND SELECTIVE INHIBITOR OF HCV NS5A

    Article • Journal of Hepatology, March 2011, Elsevier

    Dr Robert K Hamatake

  19. 818 PRECLINICAL CHARACTERIZATION OF GSK2485852, A NOVEL HCV POLYMERASE INHIBITOR

    Article • Journal of Hepatology, March 2011, Elsevier

    Dr Robert K Hamatake

  20. RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer

    Article • Cancer Research, August 2009, American Association for Cancer Research (AACR)

    Dr Robert K Hamatake

  21. 577 POSTER Selective MEK Inhibitor RDEA119 exhibits efficacy in orthotopic hepatoma models and cytostatic potential in multiple cell based models of cancer

    Article • European Journal of Cancer Supplements, October 2008, Elsevier

    Dr Robert K Hamatake

  22. A Novel NNRTI Class with Potent Anti-HIV Activity Against NNRTI-resistant Viruses

    Article • Antiviral Research, May 2008, Elsevier

    Dr Robert K Hamatake

  23. Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition

    Article • Antimicrobial Agents and Chemotherapy, December 2007, ASM Journals

    Dr Robert K Hamatake

  24. Cyclic Monophosphate Prodrugs of Base-Modified 2′-C-Methyl Ribonucleosides as Potent Inhibitors of Hepatitis C Virus RNA Replication.

    Article • ChemInform, September 2007, Wiley

    Dr Robert K Hamatake

  25. Identification and Structure—Activity Relationships of Substituted Pyridones as Inhibitors of Pim-1 Kinase.

    Article • ChemInform, July 2007, Wiley

    Dr Robert K Hamatake

  26. 6-Hydrazinopurine 2′-methyl ribonucleosides and their 5′-monophosphate prodrugs as potent hepatitis C virus inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, May 2007, Elsevier

    Dr Robert K Hamatake

  27. Cyclic monophosphate prodrugs of base-modified 2′-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication

    Article • Bioorganic & Medicinal Chemistry Letters, May 2007, Elsevier

    Dr Robert K Hamatake

  28. Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: Convergence of structure-based drug design and X-ray crystallographic study

    Article • Bioorganic & Medicinal Chemistry Letters, April 2007, Elsevier

    Dr Robert K Hamatake

  29. Identification and structure–activity relationships of substituted pyridones as inhibitors of Pim-1 kinase

    Article • Bioorganic & Medicinal Chemistry Letters, March 2007, Elsevier

    Dr Robert K Hamatake

  30. Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure

    Article • Bioorganic & Medicinal Chemistry Letters, January 2007, Elsevier

    Dr Robert K Hamatake

  31. Isothiazoles as active-site inhibitors of HCV NS5B polymerase

    Article • Bioorganic & Medicinal Chemistry Letters, January 2007, Elsevier

    Dr Robert K Hamatake

  32. A Novel Nonnucleoside Analogue That Inhibits Human Immunodeficiency Virus Type 1 Isolates Resistant to Current Nonnucleoside Reverse Transcriptase Inhibitors

    Article • Antimicrobial Agents and Chemotherapy, November 2006, ASM Journals

    Dr Robert K Hamatake

  33. Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, November 2006, Elsevier

    Dr Robert K Hamatake

  34. Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, November 2006, Elsevier

    Dr Robert K Hamatake

  35. Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase

    Article • Bioorganic & Medicinal Chemistry Letters, September 2006, Elsevier

    Dr Robert K Hamatake

  36. Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, August 2006, Elsevier

    Dr Robert K Hamatake

  37. Novel Nonnucleoside Inhibitors That Select Nucleoside Inhibitor Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase

    Article • Antimicrobial Agents and Chemotherapy, July 2006, ASM Journals

    Dr Robert K Hamatake

  38. Hepatitis B and D Protocols–Volume I: Detection, Genotypes, and Characterization. Robert K. Hamatake and Johnson Y.N. Lau, editors. Totowa, NJ: Humana Press, 2004, 374 pp., $125.00, hardcover. ISBN 1-58829-105-7.

    Article • Clinical Chemistry, February 2005, Oxford University Press (OUP)

    Dr Robert K Hamatake

  39. Hepatitis B and D Protocols–Volume II: Immunology, Model Systems, and Clinical Studies. Robert K. Hamatake and Johnson Y.N. Lau, editors. Totowa, NJ: Humana Press, 2004, 596 pp., $135.00, hardcover. ISBN 1-58829-108-1.

    Article • Clinical Chemistry, February 2005, Oxford University Press (OUP)

    Dr Robert K Hamatake

  40. Hepatitis B and D Protocols

    Article • February 2004, Springer Science + Business Media

    Dr Robert K Hamatake

  41. Hepatitis B and D Protocols

    Article • February 2004, Springer Science + Business Media

    Dr Robert K Hamatake

  42. The Rep Protein of Adeno-Associated Virus Type 2 Interacts with Single-Stranded DNA-Binding Proteins That Enhance Viral Replication

    Article • Journal of Virology, January 2004, ASM Journals

    Dr Robert K Hamatake

  43. HEP DART 2003: Frontiers in Drug Development for Viral Hepatitis

    Article • Expert Opinion on Investigational Drugs, January 2004, Informa Healthcare

    Dr Robert K Hamatake

  44. Agents in clinical development for the treatment of chronic hepatitis B

    Article • Expert Opinion on Investigational Drugs, January 2003, Informa Healthcare

    Dr Robert K Hamatake

  45. Antiviral Agents for Hepatitis Viruses

    Article • January 2002, Springer Science + Business Media

    Dr Robert K Hamatake

  46. De Novo Initiation of RNA Synthesis by the RNA-Dependent RNA Polymerase (NS5B) of Hepatitis C Virus

    Article • Journal of Virology, January 2000, ASM Journals

    Dr Robert K Hamatake

  47. Establishment of an in vitro Assay to Characterize Hepatitis C Virus NS3-4A Protease Trans-Processing Activity

    Article • Intervirology, January 1996, Karger Publishers

    Dr Robert K Hamatake

  48. Characterization of monoclonal antibodies recognizing amino- and carboxy-terminal epitopes of the herpes simplex virus UL42 protein

    Article • Virus Research, October 1995, Elsevier

    Dr Robert K Hamatake

  49. The herpes simplex virus type 1 DNA polymerase accessory protein, UL42, contains a functional protease-resistant domain

    Article • Journal of General Virology, October 1993, Society for General Microbiology

    Dr Robert K Hamatake

  50. DPB2, the gene encoding DNA polymerase II subunit B, is required for chromosome replication in Saccharomyces cerevisiae.

    Article • Proceedings of the National Academy of Sciences, June 1991, Proceedings of the National Academy of Sciences

    Dr Robert K Hamatake

  51. Cloning DPB3 , the gene encoding the third subunit of DNA polymerase II of Saccharomyces cerevisiae

    Article • Nucleic Acids Research, January 1991, Oxford University Press (OUP)

    Dr Robert K Hamatake

  52. A third essential DNA polymerase in S. cerevisiae

    Article • Cell, September 1990, Elsevier

    Dr Robert K Hamatake

  53. The J gene of ?X174: Isolation and characterization of a J gene mutant

    Article • January 1988, Springer Science + Business Media

    Dr Robert K Hamatake

  54. In vitro synthesis of bacteriophage phi X174 by purified components.

    Article • Proceedings of the National Academy of Sciences, July 1983, Proceedings of the National Academy of Sciences

    Dr Robert K Hamatake

  55. Morphogenesis of phi X174: in vitro synthesis of infectious phage from purified viral components.

    Article • Proceedings of the National Academy of Sciences, December 1981, Proceedings of the National Academy of Sciences

    Dr Robert K Hamatake

  56. Role of DNA gyrase subunits in synthesis of bacteriophage phi X174 viral DNA.

    Article • Proceedings of the National Academy of Sciences, March 1981, Proceedings of the National Academy of Sciences

    Dr Robert K Hamatake

  57. Isolation and identification of bacteriophage phi X174 prohead.

    Article • Proceedings of the National Academy of Sciences, October 1979, Proceedings of the National Academy of Sciences

    Dr Robert K Hamatake